^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Non Small Cell Lung Cancer
    Drug:Cyramza (ramucirumab) (VEGFR-2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    12/19/2014
    Excerpt:
    Cyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.
    Secondary therapy:
    docetaxel
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    CYRAMZA® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated...in combination with docetaxel, for treatment of metastatic nonsmall cell lung cancer with disease progression onor after platinum-based chemotherapy.
    Secondary therapy:
    docetaxel
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    For patients with metastatic NSCLC who progress on combination therapy with PD-1/PD-L1 inhibitors/chemotherapy, subsequent therapy with docetaxel (with or without ramucirumab), pemetrexed (non squamous only), or gemcitabine is recommended...
    Secondary therapy:
    pemetrexed; docetaxel; gemcitabine